Summary of BLLN Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $109 million, a 64% increase year-over-year.

Prenatal Revenue: $95.8 million, up 56% year-over-year.

Oncology Revenue: $13.7 million, a significant 176% increase year-over-year.

Test Volume: Grew 35% year-over-year, totaling approximately 196,000 tests.

Gross Margin: 70.5%, up 5 percentage points from the previous year.

Operating Income: $5.5 million, representing a 5% operating margin.

Adjusted EBITDA Margin: 15%.

Cash Position: Increased to $549 million.

Free Cash Flow: $5.1 million for the quarter.

2Strategic Updates and Business Highlights

Product Launches:

UnityConfirm: A non-invasive confirmation assay for high-risk pregnancies launched on May 28, showing strong adoption.

Expanded UNITY Fetal Antigen Screen: Launching a 130-gene panel on August 17, enhancing the service market.

North Star Response: Clinical evidence published supporting its use in monitoring immunotherapy, with plans for MolDX coverage expected by year-end.

Sales Expansion: Added 70 sales representatives in the first half of the year to drive future growth, particularly in health systems.

Integration with Epic Aura: Achieved rapid integration, with first orders expected to follow in 2-4 quarters.

3Forward Guidance and Outlook

2026 Revenue Guidance: Reiterated total revenue outlook of $450 million to $465 million, reflecting a growth of approximately 48% to 52% compared to 2025.

Profitability: Expected to maintain profitability levels despite ongoing investments.

4Bad News, Challenges, or Points of Concern

True-Up Revenue: Decreased from $9.2 million in Q1 to $2.8 million in Q2, impacting reported revenue.

ASP Dynamics: Although ASP increased year-over-year, there was a sequential decline of about $20 due to true-up timing.

Competitive Pressures: The market remains competitive, with ongoing challenges in gaining market share, particularly in prenatal testing.

Operational Risks: Potential delays in claims processing could affect cash flow and revenue recognition.

5Notable Q&A Insights

True-Up Impact: Management confirmed that prenatal test revenue increased sequentially when excluding true-up revenue.

Competitive Landscape: The company is not currently facing significant friction in the market but acknowledges the competitive environment.

Volume Trends: Oncology test volumes are exceeding expectations, and management is optimistic about continued growth.

Integration Timelines: While integration with health systems is progressing, the actual onboarding process can take 2-4 quarters, affecting short-term revenue growth.

Economic Considerations: New product launches like NorthStar Origin are expected to drive adoption but may not significantly alter economics in the short term. Overall, BLLN reported strong financial performance in Q2 2026, with significant revenue growth and a solid cash position, while also outlining strategic initiatives aimed at sustaining this momentum. However, challenges related to true-up revenue, competitive pressures, and integration timelines remain key considerations for investors.